Cargando…
Clinically relevant reductions in HbA(1c) without hypoglycaemia: results across four studies of saxagliptin
BackgroundIn four 24-week controlled studies, the antihyperglycaemic efficacy of saxagliptin was demonstrated in patients with type 2 diabetes mellitus as add-on therapy to glyburide, a thiazolidinedione, or metformin, and when used in initial combination with metformin vs. metformin monotherapy in...
Autores principales: | Karyekar, C S, Frederich, R, Ravichandran, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Ltd.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842088/ https://www.ncbi.nlm.nih.gov/pubmed/23795975 http://dx.doi.org/10.1111/ijcp.12212 |
Ejemplares similares
-
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
por: Karyekar, Chetan S, et al.
Publicado: (2013) -
HbA1c: an independent risk factor for dysthyroid optic neuropathy
por: Wang, Xing, et al.
Publicado: (2023) -
Evaluation of HbA1c from CGM traces in an Indian population
por: Majumdar, Sayantan, et al.
Publicado: (2023) -
Prediabetes: Adherence to Nutrition Visits Decreases HbA1c in Children and Adolescents
por: Parajuli, Sadichchha, et al.
Publicado: (2022) -
The association between maternal HbA1c and adverse outcomes in gestational diabetes
por: Muhuza, Marie Parfaite Uwimana, et al.
Publicado: (2023)